Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Print this page Email this page Users Online: 468
ORIGINAL ARTICLE
Year : 2020  |  Volume : 13  |  Issue : 4  |  Page : 306-310

Evaluation of carbohydrate antigen 19-9 levels in subjects with diabetes mellitus in Nnamdi Azikiwe university teaching hospital, Nnewi, Nigeria


1 Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, Nnamdi Azikiwe University, Nnewi Campus, Nnewi, Nigeria
2 Center for Clinical Research in Nigeria, Enugu State, Nigeria
3 Department of Biochemistry, Tansian University, Umunya, Anambra State, Nigeria
4 Department of Pathology, Clinical Biochemistry, East Kent Hospital University, NHS Foundation Trust, Kent
5 Department of Respiratory Medicine, Royal Sussex County Hospital, Brighton, England, UK

Correspondence Address:
O Ekuma-Okereke
Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, Nnamdi Azikiwe University, Nnewi Campus, Nnewi, Anambra State
Nigeria
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/mjdrdypu.mjdrdypu_156_19

Rights and Permissions

Background of Study: Diabetes mellitus (DM) is a multisystemic disorder characterized by hyperglycemia and damage to vital organs most notably the exocrine tissue and islet cells. Carbohydrate antigen 19-9 (CA 19-9) is a glycolipid antigen produced by the exocrine pancreas. Thus, it could be a useful indicator of the intensity of cellular damage to the exocrine pancreas by disease conditions such as DM. Aim: This was a case–control study aimed at evaluating the serum level of CA 19-9 as a diagnostic tool in patients with DM. Materials and Methods: A total of 90 patients aged 20–70 years were randomly selected in this study. They comprised 50 diabetic individuals as test patients and 40 aged-matched apparently healthy individuals as controls. The fasting plasma glucose (FPG) levels were determined spectrophotometrically using the glucose oxidase method, whereas the serum level of CA 19-9 was estimated photometrically using the sandwich enzyme-linked immunosorbent assay technique. Results: There was a statistically significant elevation of CA 19-9 in patients with DM compared to the nondiabetic individuals (P < 0.05). The correlation coefficient between CA 19–9 levels and age in patients with DM showed a nonsignificant positive relationship (r = 0.265, P = 0.063). A nonsignificant positive correlation was also observed when the mean level of CA 19-9 was correlated with the mean plasma level of FPG in patients with DM (r = 0.021, P = 0.884). Conclusion: The significantly elevated serum level of CA 19-9 along with its positive correlation with FPG indicates the need for a careful evaluation of blood glucose regulation while suggesting that CA 19–9 could be a suitable marker to predict chronic inflammatory complications in patients with DM. Hence, further evaluation with a duration of diabetes and glycemic control using glycated hemoglobin to ascertain the relevance of CA 19–9 in glycemic control in individuals with DM.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed189    
    Printed16    
    Emailed0    
    PDF Downloaded36    
    Comments [Add]    

Recommend this journal